We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
Date | Subject | Author | Discuss |
---|---|---|---|
31/3/2021 09:58 | Flip Flop In a major about-face, Germany will halt the use of AstraZeneca's Covid vaccine for people younger than 60 today, just two months after recommending it only for younger cohorts, and later expanding it to all age groups. Germany’s move follows a report from the country’s vaccine agency of a rare brain blood clot in 31 people, nine of whom died. With the exception of two people, all of the cases were women between the ages of 20 and 63. The development is a fresh blow for Astra’s vaccine -- and another threat to Europe’s inoculation campaign, which has already experienced delays, controversy and political battles. Bloomberg | philanderer | |
30/3/2021 18:14 | So why does that affect the share price when they are providing it for for free?Makes no bloody sense. | gateside | |
30/3/2021 18:13 | AstraZeneca finished down 1.4% after the German state of Berlin said it is again suspending the use of the drugmaker's coronavirus vaccine for people under 60 due to reports of blood clots. In addition, Canada on Monday suspended use of AstraZeneca's Covid vaccine for those under 55 amid blood clot fears. Alliance News | philanderer | |
30/3/2021 12:20 | AstraZeneca vaccine - was it really worth it? "It's appalling the way AstraZeneca has been treated. I wouldn't blame them if they were thoroughly fed up and decided to bow out of the covid vaccine business." That was the view from one of the biggest institutional investors in the UK. article: | philanderer | |
30/3/2021 00:23 | ROB GILLIES Mon, 29 March 2021, 6:45 pm TORONTO (AP) — Canada on Monday suspended the use of the Oxford-AstraZeneca coronavirus vaccine for people under age 55 following concerns it might be linked to rare blood clots. The National Advisory Committee on Immunization had recommended the pause for safety reasons and the Canadian provinces, which administer health in the country, announced the suspension Monday. “There is substantial uncertainty about the benefit of providing AstraZeneca Covid-19 vaccines to adults under 55 given the potential risks,” said Dr. Shelley Deeks, vice chair of the National Advisory Committee on Immunization. Deeks said the updated recommendations come amid new data from Europe that suggests the risk of blood clots is now potentially as high as one in 100,000, much higher than the one in one million risk believed before. She said most of the patients in Europe who developed a rare blood clot after vaccination with AstraZeneca were women under age 55, and the fatality rate among those who develop clots is as high as 40%. Dr. Joss Reimer of Manitoba’s Vaccine Implementation Task Force said despite the finding that there was no increase risk of blood clots overall related to AstraZeneca in Europe, a rare but very serious side effect has been seen primarily in young women in Europe. Reimer said the rare type of blood clot typically happens between four and 20 days after getting the shot and the symptoms can mirror a stroke or a heart attack. “While we still believe the benefits for all ages outweigh the risks I’m not comfortable with probably. I want to see more data coming out of Europe so I know exactly what this risk benefit analysis is,” Reimer said. The AstraZeneca shot, which has been authorized in more than 70 countries, is a pillar of a U.N.-backed project known as COVAX that aims to get COVID-19 vaccines to poorer countries. It has also become a key tool in European countries’ efforts to boost their sluggish vaccine rollouts. That makes doubts about the shots especially worrying. “This vaccine has had all the ups and downs. It looks like a roller coaster,” said Dr. Caroline Quach-Thanh, the chair of the National Advisory Committee on Immunization, when asked if the latest news will lead to further vaccine hesitancy. Health Canada said it has not received any reports of blood clots in Canada, and the department’s chief medical adviser, Dr. Supriya Sharma, said she still believes the vaccine’s benefits outweigh the risks. Last week, the department changed its label on the vaccine to warn about the rare risk of blood clots. Only those 60 and above have received AstraZeneca in Ontario, Canada's most populous province. “We have no concerns with those who have received it so far,” said Dr. David Williams, Ontario's chief medical officer. Mark Mendelson, a 63-year-old Toronto man who has had heart surgery, said that he has no regrets about getting his first AstraZeneca dose two weeks ago and that he will get the second. “Get what you can,” Mendelson said. “I had no ill effects at all from the AstraZeneca. I am in a better position than those who don’t have any vaccine at all. If you are betting person you would take those odds any day of the week. I’m quite prepared to roll the dice.” Several European countries that had suspended using the vaccine over concerns it could cause blood clots have resumed administering it after the EU’s drug regulator said the vaccine was safe. The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then more recently the scare about clots that had some countries temporarily pausing inoculations. Canada is expected to receive 1.5 million doses of AstraZeneca from the U.S. this week. “The messaging has been brutal overall. I am fearful it is toast. It shouldn't be," said Dr. Andrew Morris, a professor of infectious diseases at the University of Toronto and the medical director of the Antimicrobial Stewardship Program at Sinai-University Health Network. Morris thinks those who are at a high risk for a bad COVID-19 outcome and over the age of 55 should get AstraZeneca if the other vaccines are not available to them, especially during a third wave of coronavirus infections. Canadian regulators approved the Pfizer, Moderna, AstraZeneca and Johnson & Johnson vaccines. Canada has placed bigger bets on Pfizer and Moderna, ordering up to 76 million doses of Pfizer and up to 44 million of Moderna, compared with up to 20 million of AstraZeneca. It's not known when Canada will receive its first shipment of Johnson & Johnson. Canada has lagged on vaccinating its population because it lacks the ability to manufacture the vaccine and has had to rely on the global supply chain for the lifesaving shots, like many other countries. With no domestic supply, Prime Minister Justin Trudeau’s government bet on seven different vaccines manufactured elsewhere and secured advance purchase agreements — enough to get 10 doses for each of Canada’s 38 million people. While acquiring them has proven difficult, deliveries have ramped up this month. Canada expects to have more than 36.5 million doses by July and officials hope to get at least one dose into all adults who want one by the end of June. The National Advisory Committee on Immunization earlier recommended a four-month delay between doses after data from the U.K. and Quebec showed a good level of protection offered by the first shot. The U.K. has instituted a similar delay. | johncasey | |
29/3/2021 15:30 | BUPA : REFUSING to cover adverse reactions from an "experimental treatment" [Covid19 Vaccines | jimarilo | |
29/3/2021 14:35 | AstraZeneca boss is returning to Europe from Australian home as he battles public relations crisis over firm's Covid vaccine | philanderer | |
29/3/2021 12:38 | Ten stages of genocide | jimarilo | |
29/3/2021 12:04 | Pure evil ! Anyone that thinks de-population is a theory, needs to sit down with a large drink and watch this. It has been happening for years....and by the same people C19 Swab for brain cancer. "they're killing us!" | jimarilo | |
29/3/2021 11:24 | Nice dividend paid into my EQI account this morning :-) | philanderer | |
29/3/2021 09:56 | https://www.nasdaq.c | nick100 | |
26/3/2021 19:07 | Thanks AstraZeneca for being a better investment than GSK and for my AstraZeneca injection today :-) | gateside | |
26/3/2021 17:00 | After all the bad mouthing AZ has taken over the past 3 months it amazes me that they are still pursuing a policy of selling their vaccine on a not-for-profit basis. If their contracts people have any nouse at all they should have put a market flex clause in their contracts and I would urge them to use it against any country or supra-national body that is making life difficult for them. A policy of espousing genuine humanitarian concern has been been totally undermined by too many tin pot politicians. Being the good guys hasn't been entirely successful here. | ygor705 | |
26/3/2021 14:10 | I felt a bit tired out for a few hrs, that was it. The first dose is only 0.5 ml. | essentialinvestor | |
26/3/2021 13:54 | Sky news breaking, R rate rises slightly. Testing and vaccines will be around for a long time. | montyhedge | |
26/3/2021 11:36 | Scientists see if AstraZeneca vaccine can be used as a nasal spray | philanderer | |
26/3/2021 10:25 | yes in July any vaccines will be at extra cost, if EU don't want it, most of the world want it. lol | onehanded | |
26/3/2021 10:23 | Time to put the price up! | ianood | |
26/3/2021 08:51 | The EU's attacking* of the AZ vaccine is really quite vile (*while also demanding it) | stocktastic | |
26/3/2021 00:53 | Very bullying behaviour! | growthpotential |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions